IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models
Marisa Carbonaro, Kehui Wang, Hui Huang, Davor Frleta, Aditi Khatri Patel, Alexander Pennington, Mathieu Desclaux, Sven Møller-Tank, Justin C. Grindley, Judith Y. Altarejos, Jun Zhong, Greg Polites, William Poueymirou, Stephen R. Jaspers, Christos A. Kyratsous, Brian Zambrowicz, Andrew Murphy, John Lin, Lynn E. Macdonald, Christopher Daly, Mark W. Sleeman, Gavin Thurston, Zhe Li
Abstract
Liver steatosis is an increasing health issue with few therapeutic options, partly because of a paucity of experimental models. In humanized liver rodent models, abnormal lipid accumulation in transplanted human hepatocytes occurs spontaneously. Here, we demonstrate that this abnormality is associated with compromised interleukin-6 (IL-6)–glycoprotein 130 (GP130) signaling in human hepatocytes because of incompatibility between host rodent IL-6 and human IL-6 receptor (IL-6R) on donor hepatocytes. Restoration of hepatic IL-6–GP130 signaling, through ectopic expression of rodent IL-6R, constitutive activation of GP130 in human hepatocytes, or humanization of an Il6 allele in recipient mice, substantially reduced hepatosteatosis. Notably, providing human Kupffer cells via hematopoietic stem cell engraftment in humanized liver mice also corrected the abnormality. Our observations suggest an important role of IL-6–GP130 pathway in regulating lipid accumulation in hepatocytes and not only provide a method to improve humanized liver models but also suggest therapeutic potential for manipulating GP130 signaling in human liver steatosis.